MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells

Autor: Teoh G, Urashima M, Atsushi Ogata, Chauhan D, Ja, Decaprio, Sp, Treon, Rl, Schlossman, Kc, Anderson

Publikováno v: Europe PubMed Central

The murine double minute 2 (MDM2) protein facilitates G1 to S phase transition by activation of E2F-1 and can enhance cell survival by suppressing wild-type p53 (wtp53) function. In this study, we examined MDM2 expression and function in multiple mye

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3b727c4c97cd2b54aca321ba352c5b1e
https://pubmed.ncbi.nlm.nih.gov/9292533

Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells

Autor: Urashima M, Teoh G, Chauhan D, Hoshi Y, Atsushi Ogata, Sp, Treon, Rl, Schlossman, Kc, Anderson

Publikováno v: Europe PubMed Central

Interleukin-6 (IL-6) is a growth factor for multiple myeloma (MM) cells and can inhibit MM cell apoptosis. Our recent studies show that IL-6 facilitates MM cell growth via phosphorylation of retinoblastoma protein (pRB); however, the effects of IL-6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::78c52a053ca4b308485e928b353fbc78
http://europepmc.org/abstract/med/9207463

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Autor: Yee AJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Laubach JP; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Campagnaro EL; University of Michigan Cancer Center, Ann Arbor, Michigan, United States., Lipe BC; University of Rochester Medical Center, Rochester, New York, United States., Nadeem O; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Friedman RS; Newton Wellesley Hospital, Newton, Massachusetts, United States., Cole CE; University of Michigan Cancer Center, United States., O'Donnell E; Dana-Farber Cancer, United States., Bianchi G; Dana-Farber Cancer, United States., Branagan AR; Massachusetts General Hospital, Boston, Massachusetts, United States., Schlossman RL; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Shaprio SJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Harrington CC; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Burke JN; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Gammon MT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Lively KJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Reimonn CA; University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States., Andrade DX; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Redd RA; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Lohr JG; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Anderson KC; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States., Raje N; Massachusetts General Hospital, Boston, Massachusetts, United States.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 03. Date of Electronic Publication: 2024 Dec 03.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Autor: Richardson PG; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Jacobus SJ; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Weller EA; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Hassoun H; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Lonial S; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Raje NS; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Medvedova E; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., McCarthy PL; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Libby EN; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Voorhees PM; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Orlowski RZ; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Anderson LD Jr; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Zonder JA; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Milner CP; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Gasparetto C; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Agha ME; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Khan AM; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Hurd DD; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Gowin K; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Kamble RT; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Jagannath S; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Nathwani N; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Alsina M; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Cornell RF; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Hashmi H; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Campagnaro EL; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Andreescu AC; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Gentile T; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Liedtke M; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Godby KN; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Cohen AD; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Openshaw TH; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Pasquini MC; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Giralt SA; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Kaufman JL; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Yee AJ; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Scott E; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Torka P; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Foley A; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Fulciniti M; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Hebert K; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Samur MK; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Masone K; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Maglio ME; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Zeytoonjian AA; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Nadeem O; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Schlossman RL; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Laubach JP; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Paba-Prada C; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Ghobrial IM; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Perrot A; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Moreau P; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Avet-Loiseau H; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Attal M; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Anderson KC; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France., Munshi NC; From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France.

Publikováno v: The New England journal of medicine [N Engl J Med] 2022 Jul 14; Vol. 387 (2), pp. 132-147. Date of Electronic Publication: 2022 Jun 05.

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.

Autor: Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Leventhal M; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Gibson CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Manier S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Department of Hematology, CHU, Univ. Lille, 59000, Lille, France.; INSERM UMR-S1172, 59000, Lille, France., Nassar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., Capelletti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Hornburg K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Dumke H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Itani MM; Massachusetts General Hospital, Boston, MA, 02114, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Liu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., AlDubayan SH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Reardon B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Keats JJ; Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA., Stewart C; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Mehr S; Multiple Myeloma Research Foundation, Norwalk, CT, 06851, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, 06851, USA., Schlossman RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Steensma DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA., Getz G; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.; Massachusetts General Hospital, Boston, MA, 02114, USA., Neuberg DS; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA. irene_ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, 02115, USA. irene_ghobrial@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. irene_ghobrial@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2020 Jun 12; Vol. 11 (1), pp. 2996. Date of Electronic Publication: 2020 Jun 12.